<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[healthcare and sec Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/healthcare+and+sec.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to healthcare and sec]]></description>
	<s:counts start="0" returned="20" found="533" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Healthcare Roundup: CBO Scores Senate Bill, SEC Probes HCA, Global Cap on Trial in Mass., and More]]></title>
		<link><![CDATA[http://industry.bnet.com/healthcare/10001239/healthcare-roundupcbo-scores-senate-bill-sec-probes-hca-global-cap-on-trial-in-mass-and-more/]]></link>
		<description><![CDATA[Healthcare roundup of recent news by Ken Terry]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 08 Oct 2009 15:18:45 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/health+care.html"><![CDATA[Health Care]]></category>
		<category domain="http://resources.bnet.com/topic/hca+inc..html"><![CDATA[HCA Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+senate.html"><![CDATA[U.S. Senate]]></category>
		<category domain="http://resources.bnet.com/topic/vertical+industries.html"><![CDATA[Vertical Industries]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/ken+terry.html"><![CDATA[Ken Terry]]></category>
	</item>
	<item>
		<title><![CDATA[SEC Probing Apple over Jobs' Health]]></title>
		<link><![CDATA[http://blogs.bnet.com/ceo/?p=1655]]></link>
		<description><![CDATA[Remember the 1993 movie 'Dave" where Kevin Kline starred as a fill-in for the U.S. president who had slipped into a coma?    That kind of situation may have been strangely on minds of Securities & Exchange Commission regulators who are poring over Apple Inc.'s files to see...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 21 Jan 2009 09:53:41 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/job.html"><![CDATA[Job]]></category>
		<category domain="http://resources.bnet.com/topic/steve+jobs.html"><![CDATA[Steve Jobs]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/health+care.html"><![CDATA[Health Care]]></category>
		<category domain="http://resources.bnet.com/topic/apple+inc..html"><![CDATA[Apple Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/vertical+industries.html"><![CDATA[Vertical Industries]]></category>
		<category domain="http://resources.bnet.com/topic/financial+services.html"><![CDATA[Financial Services]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/enterprise+software.html"><![CDATA[Enterprise Software]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[Software]]></category>
		<category domain="http://resources.bnet.com/topic/peter+galuszka.html"><![CDATA[Peter Galuszka]]></category>
		<category domain="http://resources.bnet.com/topic/peter+galuszka.html"><![CDATA[Peter Galuszka]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AAPL</category>
		<category domain="tickers">AAPL</category>
	</item>
	<item>
		<title><![CDATA[PhytoMedical's In Vivo Toxicity and Efficacy Tests on Human Colon Cancer Deliver Promising Results]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_27/ai_n30935676]]></link>
		<description><![CDATA[Anti-cancer compound exhibits significant efficacy and toxicity values leading to further development  PRINCETON, N.J. -- PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced the results of its anti-cancer compound in vivo toxicity and efficacy tests on HCT116 human colon cancer cells was successful. "I am encouraged by the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 27 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[RegeneRx Sponsors "Walk a Mile in My Shoes" for National Epidermolysis Bullosa Awareness Week]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_24/ai_n30932989]]></link>
		<description><![CDATA[BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it is a major sponsor of "Walk a Mile in My Shoes," the signature event of National Epidermolysis Bullosa EB Awareness Week. The "Walk a Mile in My Shoes" program coordinates events that include rallies, meetings and walk-a-thons in...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 24 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/regenerx+biopharmaceuticals+inc..html"><![CDATA[RegeneRX Biopharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/wound.html"><![CDATA[wound]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">RGN</category>
		<category domain="tickers">RGN</category>
	</item>
	<item>
		<title><![CDATA[RegeneRx President and CEO to Speak at 7th Annual BIO Investor Forum]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_22/ai_n30918250]]></link>
		<description><![CDATA[BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) announced today that J.J. Finkelstein, RegeneRx's president and chief executive officer, will present a company update at the 7th Annual BIO Investor Forum in San Francisco, CA, on Thursday, October 30, 2008 at 2:00 p.m. ET. To listen and view the presentation investors...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 22 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/regenerx+biopharmaceuticals+inc..html"><![CDATA[RegeneRX Biopharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">RGN</category>
		<category domain="tickers">RGN</category>
	</item>
	<item>
		<title><![CDATA[Velcera Announces Voluntary Termination of Registration With the SEC]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200810/ai_n30921764]]></link>
		<description><![CDATA[Velcera, Inc. (OTCBB: VLCR), a specialty pharmaceutical company focused on pet health, announced today that it has filed a Form 15 with the Securities and Exchange Commission ("SEC").  As a result, effective immediately, the Company's obligation to file reports with the SEC has terminated. The SEC has 90 days...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 17 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[SOFTWARE]]></category>
		<category domain="http://resources.bnet.com/topic/termination.html"><![CDATA[termination]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[QuadraMed Corporation Repurchases 620,614 Common Shares from Single Holder]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_16/ai_n30907307]]></link>
		<description><![CDATA[RESTON, Va. -- QuadraMed Corporation (NASDAQ:QDHC) announced today that it has entered into an agreement to purchase 620,614 of its common shares from a single shareholder, at $5.50 per share, for a total purchase price of approximately $3.4 million. The Company will use its available cash to pay the purchase...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 16 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/financial.html"><![CDATA[financial]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/quadramed+corp..html"><![CDATA[QuadraMed Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[SOFTWARE]]></category>
		<category domain="http://resources.bnet.com/topic/stock.html"><![CDATA[stock]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">QD</category>
		<category domain="tickers">QD</category>
	</item>
	<item>
		<title><![CDATA[Omrix Biopharmaceuticals Receives Approval from European Medicines Agency for Evicel Liquid Fibrin Sealant]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_14/ai_n30891251]]></link>
		<description><![CDATA[NEW YORK -- OMRIX Biopharmaceuticals, Inc. ("Omrix" or the "Company") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that it has received approval from the European Medicines Agency EMEA for Evicel, the Company's liquid fibrin sealant.  The EMEA's approval permits EVICEL...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 14 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agency.html"><![CDATA[agency]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/emea.html"><![CDATA[EMEA]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[MARKETING]]></category>
		<category domain="http://resources.bnet.com/topic/productivity.html"><![CDATA[PRODUCTIVITY]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[SOFTWARE]]></category>
		<category domain="http://resources.bnet.com/topic/surgery.html"><![CDATA[surgery]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Omrix Biopharmaceuticals Provides Update On Fibrin Pad U.S. Phase II Clinical Trial In Mild to Moderate Bleeding]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_9/ai_n30883347]]></link>
		<description><![CDATA[NEW YORK -- Omrix Biopharmaceuticals, Inc. ("Omrix") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that the Fibrin Pad U.S. Phase II clinical trial in mild to moderate bleeding was suspended yesterday afternoon to investigate an incident of post-operative bleeding. The Company...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 09 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[PhytoMedical Renews Sponsored Research Agreement with Dartmouth College]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_6/ai_n29477785]]></link>
		<description><![CDATA[Anti-cancer compound development results of the past year strengthen working relationship  PRINCETON, N.J. -- PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced that it is renewing its Sponsored Research Agreement with Dartmouth College. "I am extremely pleased to have extended our agreement with Dartmouth College," stated Mr. Greg...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 06 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[agreement]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/dartmouth+college.html"><![CDATA[Dartmouth College]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/u.s..html"><![CDATA[U.S.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[HepaLife&#153; Announces Expansion of Exclusive License Agreement with U.S. Government Agency for Liver Cell Line]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_1/ai_n29469695]]></link>
		<description><![CDATA[HepaLife's expanded agreement with US Department of Agriculture allows for use of patented PICM-19 liver stem cell line as a malaria infection host system, in addition to artificial liver devices and in-vitro toxicological testing platforms.  BOSTON -- HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625) today announced that...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 01 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agency.html"><![CDATA[agency]]></category>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[agreement]]></category>
		<category domain="http://resources.bnet.com/topic/cell.html"><![CDATA[Cell]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/malaria.html"><![CDATA[malaria]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/stem-cell.html"><![CDATA[stem-cell]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+department+of+agriculture.html"><![CDATA[U.S. Department of Agriculture]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+government.html"><![CDATA[U.S. Government]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[RegeneRx to Develop RGN-457 for Cystic Fibrosis]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_1/ai_n29469728]]></link>
		<description><![CDATA[RegeneRx Seeking Strategic Partnership to Address CF in U.S. and Europe  BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it is seeking a strategic partner to assist in the development of RGN-457 for the treatment of cystic fibrosis CF. RGN-457 is based on thymosin beta 4...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 01 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/regenerx+biopharmaceuticals+inc..html"><![CDATA[RegeneRX Biopharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/u.s..html"><![CDATA[U.S.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">RGN</category>
		<category domain="tickers">RGN</category>
	</item>
	<item>
		<title><![CDATA[Healthaxis Expands Relationship with HealthSCOPE Benefits, Inc]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Sept_30/ai_n29467184]]></link>
		<description><![CDATA[Signs Multi-Year IT Outsourcing Contract to Deliver Additional Outsourcing Solutions Through BPO Management Services, Inc.  IRVING, Texas -- Healthaxis, Inc., "Healthaxis" (Nasdaq: HAXS) an innovative provider of technology-enhanced, integrated business process solutions and services, including claims and benefit administration applications, web-enabled software solutions and outsourced claims related services for...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 30 Sep 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/bpo.html"><![CDATA[BPO]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/hardware.html"><![CDATA[HARDWARE]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/merger.html"><![CDATA[merger]]></category>
		<category domain="http://resources.bnet.com/topic/outsource.html"><![CDATA[outsource]]></category>
		<category domain="http://resources.bnet.com/topic/outsourcing.html"><![CDATA[Outsourcing]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[SOFTWARE]]></category>
		<category domain="http://resources.bnet.com/topic/storage.html"><![CDATA[Storage]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[SurModics Acquires CodeLink&#153; Activated Slide Business]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Sept_30/ai_n29468597]]></link>
		<description><![CDATA[EDEN PRAIRIE, Minn. -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today the acquisition of the CodeLink[TM] Activated Slide microarray business from GE Healthcare. Terms of the transaction were not disclosed.  "Our acquisition of the CodeLink Activated...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 30 Sep 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/acquisition.html"><![CDATA[acquisition]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/general+electric+co..html"><![CDATA[General Electric Co.]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[SOFTWARE]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GE</category>
		<category domain="tickers">GE</category>
	</item>
	<item>
		<title><![CDATA[RegeneRx Enrolls First Subject in RGN-352 Phase IB Clinical Trial]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Sept_22/ai_n28573662]]></link>
		<description><![CDATA[BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it has enrolled the first subject in its Phase IB clinical trial in which RGN-352 is being tested in 40 healthy subjects. RGN-352 is an injectable formulation of T4 being developed to reduce cardiac damage in patients after an...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 22 Sep 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Shionogi and Sciele Announce Receipt of United States Antitrust Clearance]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Sept_19/ai_n28571437]]></link>
		<description><![CDATA[OSAKA, Japan & ATLANTA -- Shionogi & Co., Ltd. ("Shionogi") and Sciele Pharma, Inc. ("Sciele") (NASDAQ: SCRX) announced today that the waiting period under the Hart Scott Rodino Antitrust Improvements Act of 1976 with respect to Shionogi's indirect wholly owned subsidiary's cash tender offer for all outstanding shares of common...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 19 Sep 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[SOFTWARE]]></category>
		<category domain="http://resources.bnet.com/topic/tender.html"><![CDATA[TENDER]]></category>
		<category domain="http://resources.bnet.com/topic/women.html"><![CDATA[women]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Celera Corporation Files Its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Sept_8/ai_n30883795]]></link>
		<description><![CDATA[ALAMEDA, Calif. -- Celera Corporation (NASDAQ:CRA) today filed its annual report on Form 10-K with the U.S. Securities and Exchange Commission. The annual report on Form 10-K can be accessed through Celera's website at http://www.celera.com and hard copies are available free-of-charge from the Company.  About Celera  Celera is...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 08 Sep 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/internet.html"><![CDATA[INTERNET]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[SOFTWARE]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[RegeneRx Completes Patient Enrollment of First Phase II Clinical Trial]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_August_20/ai_n28012561]]></link>
		<description><![CDATA[BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it completed enrollment of its first of four ongoing Phase II clinical trials. The trial is a double-blind, placebo-controlled, dose-escalating clinical trial evaluating the safety and efficacy of the Company's topical drug candidate, RGN-137, in seventy-two patients with pressure...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 20 Aug 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Inspire Announces Peer-Reviewed Publications Related to Denufosol for Cystic Fibrosis]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_August_6/ai_n27971408]]></link>
		<description><![CDATA[DURHAM, N.C. -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today publication of two papers related to the denufosol for cystic fibrosis development program in peer-reviewed journals.  The first paper, "Denufosol: A Review of Studies with Inhaled P2Y2 Agonists that led to Phase 3" (D. Kellerman, A. Rossi Mospan, J....]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 06 Aug 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/inspire+pharmaceuticals+inc..html"><![CDATA[Inspire Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/litigation.html"><![CDATA[Litigation]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ISPH</category>
		<category domain="tickers">ISPH</category>
	</item>
	<item>
		<title><![CDATA[Pluristem Therapeutics Announces $1.6 Million Securities Offering]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_August_6/ai_n27971549]]></link>
		<description><![CDATA[NEW YORK -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized allogeneic cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced it has entered into definitive agreements to sell common stock and warrants to selected institutional investors for aggregate...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 06 Aug 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
</channel>
</rss>
